Allergology

Intrommune Therapeutics Presents at Next Generation Food Allergy Drug Summit

Retrieved on: 
Thursday, July 22, 2021
Medical specialties, Clinical medicine, Medicine, Food allergies, Immune system, Immunology, Allergology, Allergy, Allergen immunotherapy, Immunotherapy, Kari Nadeau, Allergies in dogs

NEW YORK, July 22, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics , a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is participating in the Next Generation Food Allergy Drug Summit.

Key Points: 
  • NEW YORK, July 22, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics , a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is participating in the Next Generation Food Allergy Drug Summit.
  • Dr. Reisacher is also the inventor of oral mucosal immunotherapy (OMIT) and is a Senior Scientific Advisor to Intrommune Therapeutics.
  • Success with allergy immunotherapy hinges on consistent exposure of a patients immune system to gradually desensitize the patient to the specific allergy trigger over time.
  • Intrommune , dedicated to improving and protecting the lives of people with food allergy, is developing the revolutionary oral mucosal immunotherapy (OMIT) treatment platform for food allergies.

US Allergic Conjunctivitis Market and Competitive Landscape Report 2021: Epidemiology, Key Products Marketed, Market Valuations and Forecast, Drugs Sales and Market Shares - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 21, 2021
Research, Technology, Other Technology, Clinical trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Medical specialties, Immunology, Clinical medicine, Allergology, Conjunctivitis, Measles, Allergic conjunctivitis, Allergy

US Allergic Conjunctivitis Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Allergic Conjunctivitis pipeline products, Allergic Conjunctivitis epidemiology, Allergic Conjunctivitis market valuations and forecast, Allergic Conjunctivitis drugs sales and competitive landscape in the US.

Key Points: 
  • US Allergic Conjunctivitis Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Allergic Conjunctivitis pipeline products, Allergic Conjunctivitis epidemiology, Allergic Conjunctivitis market valuations and forecast, Allergic Conjunctivitis drugs sales and competitive landscape in the US.
  • The research is classified into seven sections - Allergic Conjunctivitis treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.
  • Allergic Conjunctivitis pipeline: Find out the products in clinical trials for the treatment of Allergic Conjunctivitis by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Allergic Conjunctivitis drugs: Identify key products marketed and prescribed for Allergic Conjunctivitis in the US, including trade name, molecule name, and company
    Allergic Conjunctivitis market valuations: Find out the market size for Allergic Conjunctivitis drugs in 2019 in the US.
  • Find out how the market advanced from 2017 and forecast to 2026
    Allergic Conjunctivitis drugs market share: Find out the market shares for key Allergic Conjunctivitis drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Allergic Conjunctivitis products

SpoonfulONE Announces Nationwide Launch In Target, Making Multi-Allergen Feeding More Accessible

Retrieved on: 
Monday, July 19, 2021
Medical specialties, Immunology, Medicine, Allergology, Immune system, Food allergy, Allergy, Kari Nadeau, Allergen, Allergist

MENLO PARK, Calif., July 19, 2021 /PRNewswire/ -- SpoonfulONE, the leader in early allergen feeding, announces the launch of their pediatrician-recommended line of nutritional products at Target.

Key Points: 
  • MENLO PARK, Calif., July 19, 2021 /PRNewswire/ -- SpoonfulONE, the leader in early allergen feeding, announces the launch of their pediatrician-recommended line of nutritional products at Target.
  • This step makes multi-allergen feeding more accessible to families and has the potential to help reduce food allergy rates across the country.
  • SpoonfulONE was developed by globally renowned pediatric allergist, Dr. Kari Nadeau in response to an alarming increase in food allergy rates.
  • About SpoonfulONE: SpoonfulONE is a revolutionary, science-backed line of nutritional products that makes food allergen introduction & maintenance safe and easy.

Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio™ Nasal Spray in Prevention and Mitigation of SARS-CoV-2

Retrieved on: 
Wednesday, July 14, 2021
Medical specialties, Clinical medicine, Medicine, Immunology, Allergology, Immunologic tests, Allergen, Immune system, Preprint, Titer

AM-301 was found to be safe in vitro, and it significantly decelerated viral titer growth in experimental models of prophylaxis and mitigation.

Key Points: 
  • AM-301 was found to be safe in vitro, and it significantly decelerated viral titer growth in experimental models of prophylaxis and mitigation.
  • The manuscript describing these preclinical data is available on a preprint server at https://www.biorxiv.org/content/10.1101/2021.07.12.452021v1 and will undergo scientific peer-review for potential publication.
  • As recently announced, Auris Medicals affiliate Altamira Medica Ltd. will start the market roll-out of Bentrio by launching it in Germany.
  • Bentrio (AM-301) is a drug-free nasal spray for personal protection against airborne viruses and allergens.

Cell Science Systems Reports Newly Discovered Cause of Delayed Food Allergies (Sensitivities)

Retrieved on: 
Tuesday, July 13, 2021
Other Consumer, Medical devices, Infectious diseases, Women, Seniors, Genetics, Fitness & Nutrition, MEN, Other Technology, Clinical trials, Family, Biotechnology, Alternative medicine, Hardware, Consumer, Health, Science, Other Science, Technology, Research, Diabetes, Nanotechnology, Stem cells, Practice Management, Managed care, General Health, Teens, Parenting, Children, Other Health, Oncology, Medical specialties, Immunology, Clinical medicine, Food allergies, Allergology, Immune system, Respiratory diseases, Allergy, Immunoglobulin E, Wheat allergy, Allergies in cats

However, researchers from University Leipzig (Germany) and Georgetown University together with Cell Science Systems may have found the key to understanding the most difficult type of food allergies know as delayed food allergies or sensitivities.

Key Points: 
  • However, researchers from University Leipzig (Germany) and Georgetown University together with Cell Science Systems may have found the key to understanding the most difficult type of food allergies know as delayed food allergies or sensitivities.
  • Delayed food allergies or sensitivities (also referred to as non-IgE mediated food allergies) are difficult to identify because symptoms are less acute and may take hours or even days to develop.
  • Hence, there is a great need for a test that can accurately and cost-effectively identify food and food product triggers of delayed food allergies.
  • ), are responsible for delayed food allergies and release more DNA, and other associated proteins, when exposed to an ALCAT Test positive food.

Global Allergy Diagnostics Market Trajectory & Analytics Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 13, 2021
Medical devices, Health, Medical specialties, Immunology, Medicine, Allergology, Allergy, Skin allergy test, Hygiene hypothesis

With Allergies on the Rise for Whatever Reason Be It Our Neanderthal Genes or Hygiene Hypothesis or Vitamin D Hypothesis, the Need for Effective Diagnostics Has Never Been Greater

Key Points: 
  • With Allergies on the Rise for Whatever Reason Be It Our Neanderthal Genes or Hygiene Hypothesis or Vitamin D Hypothesis, the Need for Effective Diagnostics Has Never Been Greater
    US Dominates the Allergy Diagnostics Market, While China to Witness the Fastest Growth
    SmartPractice Secures FDA Approval for T.R.U.E.
  • Test(R) Patch Test for Pediatric Use
    CLA-1 (TM) Luminometer In-Vitro Allergy Testing Platform for Accurate, Reliable Results
    Environmental Changes and Pollution Aggravate Incidence of Allergic Reactions, Resulting in Increased Need for Allergy Diagnostics

Stallergenes Greer Showcases Precision Medicine at 2021 EAACI Congress

Retrieved on: 
Sunday, July 11, 2021
Oncology, Health, Other Health, General Health, Clinical trials, Pharmaceutical, Biotechnology, Medical specialties, Immunology, Medicine, Allergology, Stallergenes Greer, Allergen immunotherapy, Personalized medicine, European Academy of Allergy and Clinical Immunology, Ait, Allergen, Precision medicine, Allergy

Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), announces that the company showcased its advancements in precision medicine in AIT via a company sponsored symposium entitled Supporting individual patients needs: AIT still an unmatched model of personalized medicine for allergy at the European Academy of Allergy and Clinical Immunology (EAACI) 2021 Congress in Krakow (Poland).

Key Points: 
  • Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), announces that the company showcased its advancements in precision medicine in AIT via a company sponsored symposium entitled Supporting individual patients needs: AIT still an unmatched model of personalized medicine for allergy at the European Academy of Allergy and Clinical Immunology (EAACI) 2021 Congress in Krakow (Poland).
  • Stallergenes Greer is present at the congress from July 10 to July 12 and will also present nine posters addressing precision medicine in AIT and announcing new data from clinical trials and real-world studies.
  • Precision medicine is paving the way to the future of allergen immunotherapy by exploring the mechanism of disease of each individual to provide patients with precise, personalised and targeted treatment approaches.
  • Stallergenes Greer Ltd is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France).

Stallergenes Greer and Alyatec Announce Research Collaboration to Advance Precision Medicine in Allergen Immunotherapy

Retrieved on: 
Friday, July 9, 2021
Health, Infectious diseases, Clinical trials, Research, Pharmaceutical, Science, Medical specialties, Allergology, Medicine, Clinical medicine, Stallergenes Greer, Ait, Allergen immunotherapy, Precision medicine

Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), and Alyatec, a contract research organisation based in Strasbourg University Hospital (France), today announced that they have entered into a collaboration to advance precision medicine in AIT.

Key Points: 
  • Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), and Alyatec, a contract research organisation based in Strasbourg University Hospital (France), today announced that they have entered into a collaboration to advance precision medicine in AIT.
  • This research collaboration brings together the longstanding expertise of Stallergenes Greer in AIT and Alyatecs competencies in research and clinical services as well as its state-of-the-art technology, including a new generation environmental exposure chamber.
  • We are excited about the collaboration with Alyatec which will support Stallergenes Greers ambition to advance the practice of allergology.
  • This collaboration is a remarkable opportunity for Alyatec to develop precision medicine in AIT.

WellNow Allergy Launches to Bring Convenience and Flexibility to Allergy Testing and Immunotherapy

Retrieved on: 
Tuesday, July 6, 2021
Medical specialties, Immunology, Clinical medicine, Allergology, Immune system, Allergy, Allergen immunotherapy, WellNow Urgent Care

Buffalo, NY, July 06, 2021 (GLOBE NEWSWIRE) -- WellNow Allergy , an affiliate of leading urgent care provider WellNow Urgent Care , is now accepting patients in Western New York to provide allergy sufferers of all ages with convenient, on-demand access to allergy testing and immunotherapy (also known as allergy shots).

Key Points: 
  • Buffalo, NY, July 06, 2021 (GLOBE NEWSWIRE) -- WellNow Allergy , an affiliate of leading urgent care provider WellNow Urgent Care , is now accepting patients in Western New York to provide allergy sufferers of all ages with convenient, on-demand access to allergy testing and immunotherapy (also known as allergy shots).
  • Follow-up allergy shots, if needed, can be scheduled at any of WellNow Urgent Cares seventeen locations in Western New York.
  • Theres a clear need for better access, convenience and ease when it comes to allergy diagnosis and treatment.
  • WellNow Allergy, an affiliate of WellNow Urgent Care, is a growing provider of convenient, high quality allergy care, with two allergy centers and seventeen allergy immunotherapy locations in New York.

Neosinus enters into Strategic Partnership with DailyBreath to Collaborate on Improving Allergy and Asthma Management

Retrieved on: 
Thursday, July 1, 2021
Medical specialties, Clinical medicine, Medicine, Immune system, Immunology, Allergology, Asthma, Respiratory therapy, Allergy

Considering that the nasal cavity functions as the air filter for the body, proper nasal rinsing will play a key role in allergy and asthma management.

Key Points: 
  • Considering that the nasal cavity functions as the air filter for the body, proper nasal rinsing will play a key role in allergy and asthma management.
  • Eric Klos, Founder of DailyBreath, said "DailyBreath is excited to be in partnership with Neosinus to promote the self-care steps required to improve overall breathing health.
  • DailyBreath is focused on allergy trigger management through education and awareness, that supports symptom reduction and avoidance.
  • Our vision is a world where uncertainty, fear, and suffering associated with daily breathing is lessened for those with allergy, asthma, and COPD.